Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
LPAR1 Biologics Sequence Review Report 2026: Lysophosphatidic acid receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LPAR1 Biologics Sequence Review Report 2026: Lysophosphatidic acid receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LPAR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LCOR Biologics Sequence Review Report 2026: Ligand-dependent corepressor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LCOR Biologics Sequence Review Report 2026: Ligand-dependent corepressor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LCOR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
L1CAM Biologics Sequence Review Report 2026: Neural cell adhesion molecule L1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
L1CAM Biologics Sequence Review Report 2026: Neural cell adhesion molecule L1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of L1CAM sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KITLG Biologics Sequence Review Report 2026: Kit ligand Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KITLG Biologics Sequence Review Report 2026: Kit ligand Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of KITLG sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAML Biologics Sequence Review Report 2026: Junctional adhesion molecule-like Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAML Biologics Sequence Review Report 2026: Junctional adhesion molecule-like Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of JAML sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAM3 Biologics Sequence Review Report 2026: Junctional adhesion molecule C Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAM3 Biologics Sequence Review Report 2026: Junctional adhesion molecule C Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of JAM3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAM2 Biologics Sequence Review Report 2026: Junctional adhesion molecule B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAM2 Biologics Sequence Review Report 2026: Junctional adhesion molecule B Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of JAM2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB1BP2 Biologics Sequence Review Report 2026: Integrin beta-1-binding protein 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB1BP2 Biologics Sequence Review Report 2026: Integrin beta-1-binding protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ITGB1BP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA11 Biologics Sequence Review Report 2026: Integrin alpha-11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA11 Biologics Sequence Review Report 2026: Integrin alpha-11 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ITGA11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
INSRR Biologics Sequence Review Report 2026: Insulin receptor-related protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
INSRR Biologics Sequence Review Report 2026: Insulin receptor-related protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of INSRR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFL4 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFL4 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGFL4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFL3 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFL3 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGFL3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →